Avicanna (TSE:AVCN) has released an update.
Avicanna Inc. has reported a significant revenue increase of 85% in Q2 2024, reaching $6.1 million, while also announcing the successful completion of two real-world evidence trials for medical cannabis products aimed at treating Epidermolysis Bullosa and Musculoskeletal Pain. The company highlighted a steady growth in their financial performance and advancements in their medical research, strengthening their position in the medical cannabis industry.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
